Evidence map›Paper›PMID 32055785›Full record

ArticleChronic diseases and translational medicine2019

Overcoming the challenges of cancer drug resistance through bacterial-mediated therapy.

Amin Zargar, Samantha Chang, Ankita Kothari, Antoine M Snijders, Jian-Hua Mao, Jessica Wang, Amanda C Hernández, Jay D Keasling, Trever G Bivona

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chronic diseases and translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 43 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. OptimizedInternational journal of ophthalmology · 2025
    Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. YAP at the Crossroads of Biomechanics and Drug Resistance in Human Cancer.International journal of molecular sciences · 2023
    Review
  15. Review
  16. Frontiers in cellular and infection microbiology · 2023
    Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Amin ZargarJoint BioEnergy Institute, Lawrence Berkeley National Laboratory, Emeryville, CA 94608, USA.
Samantha ChangJoint BioEnergy Institute, Lawrence Berkeley National Laboratory, Emeryville, CA 94608, USA.
Ankita KothariBiological Systems and Engineering, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA.
Antoine M SnijdersBiological Systems and Engineering, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA.
Jian-Hua MaoBiological Systems and Engineering, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA.
Jessica WangJoint BioEnergy Institute, Lawrence Berkeley National Laboratory, Emeryville, CA 94608, USA.
Amanda C HernándezJoint BioEnergy Institute, Lawrence Berkeley National Laboratory, Emeryville, CA 94608, USA.
Jay D KeaslingJoint BioEnergy Institute, Lawrence Berkeley National Laboratory, Emeryville, CA 94608, USA.
Trever G BivonaHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA.
Lawrence Berkeley National Laboratory · USJoint BioEnergy Institute · USUCSF Helen Diller Family Comprehensive Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite tremendous efforts to fight cancer, it remains a major public health problem and a leading cause of death worldwide. With increased knowledge of cancer pathways and improved technological platforms, precision therapeutics that specifically target aberrant cancer pathways have improved patient outcomes. Nevertheless, a primary cause of unsuccessful cancer therapy remains cancer drug resistance. In this review, we summarize the broad classes of resistance to cancer therapy, particularly pharmacokinetics, the tumor microenvironment, and drug resistance mechanisms. Furthermore, we describe how bacterial-mediated cancer therapy, a bygone mode of treatment, has been revitalized by synthetic biology and is uniquely suited to address the primary resistance mechanisms that confound traditional therapies. Through genetic engineering, we discuss how bacteria can be potent anticancer agents given their tumor targeting potential, anti-tumor activity, safety, and coordinated delivery of anti-cancer drugs.

Indexed as

Bacterial-mediated therapyCancer therapyDrug resistanceSynthetic biology

Identifiers

PMID32055785
PMCPMC7004931
OpenAlexW2998837516

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.